APOA1

(redirected from Apolipoprotein A1)
Also found in: Wikipedia.

APOA1

A gene on chromosome 11q23-q24 that encodes apolipoprotein A1, the main protein component of high-density lipoprotein (HDL) in plasma, which promotes cholesterol efflux from tissues to the liver for excretion and is a cofactor for lecithin cholesterolacyltransferase (LCAT), which is responsible for forming most plasma cholesteryl esters.
 
Molecular pathology
APOA1 mutations cause HDL deficiency (e.g., Tangier disease and systemic non-neuropathic amyloidosis).
References in periodicals archive ?
FBG, total cholesterol, triglyceride, HDL, LDL, apolipoprotein A1 (apo A1) and apolipoprotein B (apo B) were measured by using an auto-analyzer (Hitachi 704 Roche Diagnostics Switzerland).
After an overnight 12-h fasting period, venous blood samples were collected to analyze the following parameters: total cholesterol (using the autoanalyzer method), high- and low-density lipoprotein (HDL and LDL) cholesterol (using enzymatic colorimetry), triglycerides (using automated enzymatic methods), and apolipoprotein A1 and B (nephelometry).
Finally, each method measures a different component of HDL [i.e., apolipoprotein A1 (apo A1), cholesterol content, or particle number].
Klintrup et al., "Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer," Scientific Reports, vol.
It was found that apolipoprotein A1 (APOA1) was decreased, while serum amyloid A (SAA) was increased in these patients regarding those presenting NPnoSLE and/or CTRL groups.
Men in the highest quintile of body mass index (BMI, mean=30.5 kg/m(2)) were less physically active and had a more adverse cardiovascular lipid and homeostatic profile, as indicated by levels of insulin, triglyceride (TG), tissue plasminogen activator (t-PA) antigen levels, and apolipoprotein A1 (Apo-A1).
Emerging biomarkers, such as apolipoprotein A1, apolipoprotein B, leptin, adiponectin, free fatty acids, ghrelin and tumour necrosis factor-alpha, have been proposed as tools that could provide valuable complementary information to that obtained from traditional biomarkers.
(5) This statement addresses the perceived limitations of testing nonfasting samples by referencing data from studies that evaluated lipid variation in postprandial versus fasting states, showing that there is no change in HDL-C, apolipoprotein A1, apolipoprotein B, or lipoproteins) levels and minimal changes in TG, total cholesterol, calculated remnant cholesterol, non-HDL-C, and LDL-C values.
The serum levels of triglycerides, cholesterol and fraction, and apolipoprotein A1 were determined with the use of commercially available kits (Labtest Diagnostica S.A., Belo Horizonte, Brazil), using enzymatic methodologies or Trinder's final reaction (quinone imine formation).
A total of 14 spots were identified as follows: serotransferrin (TRFE spots 1 and 2), albumin (ALBU, spot 3 as a fragment), kininogen-1 (KNG1, spot 4), alpha-fetoprotein (FETA, spot 5), mannose-binding protein C (MBL2, spot 6), apolipoprotein A1 (APOA1, spots 7 and 8), alpha-1-antitrypsin (A1AT, spots 9, 10, and 11), CD5 antigen-like (CD5L, spot 12), alpha-2-macroglobulin (A2M, spot 13), and vitamin D-binding protein (VTDB, spot 14).
Evolocumab also improved apolipoprotein B, high density lipoprotein cholesterol (HDL-C) apolipoprotein A1, triglycerides, lipoprotein a, non-HDL-C, and total cholesterol.
(5.) Gugliucci A, Stahl AL; Invitroglycation of human apolipoprotein A1 reduces its efficiency in lecithin--cholesterol acyl transferase activity.